Infinity Pharmaceuticals Inc. (NASDAQ:INFI) – Oppenheimer issued their Q2 2019 earnings estimates for Infinity Pharmaceuticals in a note issued to investors on Wednesday, June 26th. Oppenheimer analyst K. Degeeter anticipates that the biotechnology company will post earnings of ($0.15) per share for the quarter. Oppenheimer has a “Outperform” rating and a $3.00 price target on the stock. Oppenheimer also issued estimates for Infinity Pharmaceuticals’ Q3 2019 earnings at ($0.16) EPS, Q4 2019 earnings at ($0.18) EPS, FY2019 earnings at ($0.73) EPS, FY2020 earnings at ($0.77) EPS and FY2021 earnings at ($0.91) EPS.
Other equities research analysts also recently issued research reports about the stock. ValuEngine downgraded shares of Infinity Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. CIBC assumed coverage on shares of Infinity Pharmaceuticals in a research report on Thursday, June 27th. They set an “outperform” rating for the company. Finally, Zacks Investment Research downgraded shares of Infinity Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 26th. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. Infinity Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $2.67.
Shares of INFI stock opened at $1.75 on Monday. The stock’s fifty day moving average is $1.56. Infinity Pharmaceuticals has a 12-month low of $1.00 and a 12-month high of $2.92. The company has a market capitalization of $100.77 million, a P/E ratio of -8.75 and a beta of 1.88.
Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.19). The firm had revenue of $2.14 million for the quarter, compared to the consensus estimate of $10.07 million.
A number of institutional investors and hedge funds have recently made changes to their positions in INFI. Two Sigma Securities LLC acquired a new position in Infinity Pharmaceuticals during the fourth quarter worth $40,000. Community Bank N.A. boosted its holdings in Infinity Pharmaceuticals by 71.4% during the first quarter. Community Bank N.A. now owns 24,000 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 10,000 shares during the last quarter. Alambic Investment Management L.P. acquired a new position in Infinity Pharmaceuticals during the fourth quarter worth $46,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Infinity Pharmaceuticals by 54.2% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 45,232 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 15,908 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Infinity Pharmaceuticals by 73.6% during the fourth quarter. Bank of New York Mellon Corp now owns 72,256 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 30,622 shares during the last quarter. Institutional investors and hedge funds own 54.33% of the company’s stock.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.